Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 4/20 | 0.49 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.45 |
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.40 |
| ▸ | TTBK2 | Q6IQ55 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | CCNK | O75909 | 2/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.36 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16588527 | 0.81 | PRKCI (0.59) | PRKCIBRD4AXLTTBK1TTBK2 | |
| SCHEMBL12563103 | 0.81 | PRKCI (0.54) | PRKCIBRD4AXLTTBK1TTBK2 | |
| SCHEMBL27869032 | 0.79 | BRD4 (0.46) | PRKCIBRD4AXLTTBK1TTBK2 | |
| SCHEMBL1565472 | 0.77 | PRKCI (0.53) | PRKCIAXLMAPK1CCNKCDK12 | |
| SCHEMBL26107823 | 0.76 | TTBK1 (0.49) | PRKCIAXLTTBK1TTBK2 | |
| SCHEMBL21677833 | 0.76 | BRD4 (0.43) | PRKCIBRD4AXLTTBK1TTBK2 | |
| SCHEMBL16588526 | 0.74 | BRD4 (0.42) | PRKCIBRD4AXLTTBK1TTBK2 | |
| SCHEMBL21958374 | 0.74 | PRKCI (0.50) | PRKCIAXLMAPK1AURKAAURKB | |
| SCHEMBL17963822 | 0.73 | JAK2 (0.54) | PRKCIBRD4AXLTTBK1TTBK2 | |
| SCHEMBL22620207 | 0.73 | PRKCI (0.53) | PRKCIAXLTTBK1TTBK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | AMGEN INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-117813086-A | Arylsulfonyl (hydroxy) piperidines as CCR6 inhibitors | 坎莫森特里克斯公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230133406-A1 | Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors | CHEMOCENTRYX, INC. | 2023-05-04 | — | — | US | disclosed |
| US-8785438-B2 | Imidazopyridin-2-one derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20130338156-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-19 | — | — | US | disclosed |
| US-8436012-B2 | Imidazopyridin-2-one derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8158647-B2 | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158647-B2 | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158647-B2 | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2308877-A1 | IMIDAZOPYRIDIN-2-ON DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20110082138-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2056822-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008150914-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150914-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133406-A1 | Aryl Sulfonyl (Hydroxy) Piperidines as CCR6 Inhibitors | CCR6, CCR1, CCR4 | PRKCI 4076/4885BRD4 403/4885AXL 3506/4885 |
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | CCR6, CCR1, CCR4 | PRKCI 4076/4885BRD4 403/4885AXL 3506/4885 |
| US-20110082138-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MTOR, MAPKAP1, RICTOR | PRKCI 510/4885BRD4 549/4885AXL 3069/4885 |
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | PDXK, MAP3K4, PDPK1 | PRKCI 674/4885BRD4 92/4885AXL 599/4885 |
| US-20130338156-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MTOR, MAPKAP1, RICTOR | PRKCI 510/4885BRD4 549/4885AXL 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.